Vivek Mishra works as an Assistant Editor with Eastern Eye and has over 13 years of experience in journalism. His areas of interest include politics, international affairs, current events, and sports. With a background in newsroom operations and editorial planning, he has reported and edited stories on major national and global developments.
Delhi Capitals, guided by Rishabh Pant's leadership and sharp wicketkeeping, secured a decisive six-wicket victory over Gujarat Titans, who were restricted to their IPL season-low score of 89 on Wednesday.
In the match held in Ahmedabad, Delhi's medium-pacer Mukesh Kumar delivered an outstanding performance, claiming 3-14, and playing a pivotal role in dismantling Gujarat's lineup in just 17.3 overs. Following the dismissal, Delhi efficiently chased down the target in 8.5 overs.
Despite missing the services of the injured David Warner, Delhi Capitals managed their third victory of the season and their second in a row, moving up three spots to sixth place in the league standings.
Rishabh Pant, making a comeback in this IPL season after a severe car accident, remained not out at 16, complementing Australian batsman Jake Fraser-McGurk who scored a quick 20 runs. Pant, a 26-year-old left-handed batsman, has now accumulated 210 runs this season, including two fifties, enhancing his prospects for the upcoming T20 World Cup in June.
"I'm very pleased," said Pant, who was named man of the match. "We discussed having a champion mindset, and that's been a focus in our team discussions."
Regarding his return post-recovery, Pant remarked, "My main focus coming back to the field was to improve. That was my mindset throughout my rehabilitation. I'm enjoying every match and just being on the field."
Pant's recovery followed serious injuries sustained in December 2022 when his car hit a barrier, overturned, and caught fire. He was initially hospitalized and later airlifted to Mumbai for further medical procedures.
The match saw early setbacks for Gujarat as India's fast bowler Ishant Sharma removed captain Shubman Gill in the second over. Gujarat struggled throughout their innings, losing wickets at regular intervals due to disciplined bowling from Delhi.
Defensive play from Delhi was also on point, with Sumit Kumar executing a direct throw to run out Sai Sudarshan for 12. Pant showcased his agility behind the stumps with a flying catch to dismiss David Miller off Ishant's bowling and completed two stumpings, removing Abhinav Manohar and Shahrukh Khan in quick succession.
Despite Rashid Khan’s effort to steady the innings with a gritty 31 off 24 balls, he eventually succumbed, caught behind off Pant’s glove work.
Reflecting on the team's performance, Gill stated, "Our batting was very average today, but it's important to move on and come back stronger. The pitch was fine; it didn’t contribute to the dismissals."
This season, Gujarat's score stands in stark contrast to some of the higher totals recorded, including two record-breaking scores of 277 and 287 by Sunrisers Hyderabad.
UK life sciences sector contributed £17.6bn GVA in 2021 and supports 126,000 high-skilled jobs.
Inward life sciences FDI fell by 58 per cent from £1,897m in 2021 to £795m in 2023.
Experts warn NHS underinvestment and NICE pricing rules are deterring innovation and patient access.
Investment gap
Britain is seeking to attract new pharmaceutical investment as part of its plan to strengthen the life sciences sector, Chancellor Rachel Reeves said during meetings in Washington this week. “We do need to make sure that we are an attractive place for pharmaceuticals, and that includes on pricing, but in return for that, we want to see more investment flow to Britain,” Reeves told reporters.
Recent ABPI report, ‘Creating the conditions for investment and growth’, The UK’s pharmaceutical industry is integral to both the country’s health and growth missions, contributing £17.6 billion in direct gross value added (GVA) annually and supporting 126,000 high-skilled jobs across the nation. It also invests more in research and development (R&D) than any other sector. Yet inward life sciences foreign direct investment (FDI) fell by 58per cent, from £1,897 million in 2021 to £795 million in 2023, while pharmaceutical R&D investment in the UK lagged behind global growth trends, costing an estimated £1.3 billion in lost investment in 2023 alone.
Richard Torbett, ABPI Chief Executive, noted “The UK can lead globally in medicines and vaccines, unlocking billions in R&D investment and improving patient access but only if barriers are removed and innovation rewarded.”
The UK invests just 9% of healthcare spending in medicines, compared with 17% in Spain, and only 37% of new medicines are made fully available for their licensed indications, compared to 90% in Germany.
Expert reviews
Shailesh Solanki, executive editor of Pharmacy Business, pointed that “The government’s own review shows the sector is underfunded by about £2 billion per year. To make transformation a reality, this gap must be closed with clear plans for investment in people, premises and technology.”
The National Institute for Health and Care Excellence (NICE) cost-effectiveness threshold £20,000 to £30,000 per Quality-Adjusted Life Year (QALY) — has remained unchanged for over two decades, delaying or deterring new medicine launches. Raising it is viewed as vital to attracting foreign investment, expanding patient access, and maintaining the UK’s global standing in life sciences.
Guy Oliver, General Manager for Bristol Myers Squibb UK and Ireland, noted that " the current VPAG rate is leaving UK patients behind other countries, forcing cuts to NHS partnerships, clinical trials, and workforce despite government growth ambitions".
Reeves’ push for reform, supported by the ABPI’s Competitiveness Framework, underlines Britain’s intent to stay a leading hub for pharmaceutical innovation while ensuring NHS patients will gain faster access to new treatments.
By clicking the 'Subscribe’, you agree to receive our newsletter, marketing communications and industry
partners/sponsors sharing promotional product information via email and print communication from Garavi Gujarat
Publications Ltd and subsidiaries. You have the right to withdraw your consent at any time by clicking the
unsubscribe link in our emails. We will use your email address to personalize our communications and send you
relevant offers. Your data will be stored up to 30 days after unsubscribing.
Contact us at data@amg.biz to see how we manage and store your data.